Drug Profile
BAY 1112054
Alternative Names: BAY-1112054Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Positive transcriptional elongation factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Cancer in Germany (PO)
- 01 Sep 2016 Phase-I clinical trials in Cancer in Germany (PO) before September 2016 (Bayer pipeline, September 2016)
- 29 Apr 2016 Preclinical development is ongoing in Germany